Breaking News

Globalfoundries to Buy IBM's Chip Unit; IBM Sees Pretax Charge $4.7 Billion
Tweet TWEET

Novus Biologicals Hires David Eansor to Lead New Corporate-Development Effort

Novus Biologicals Hires David Eansor to Lead New Corporate-Development Effort

Bioscience Industry Veteran to Focus on New Growth Initiatives for
Fast-Growing Antibody Provider

PR Newswire

LITTLETON, Colo., Jan. 24, 2013

LITTLETON, Colo., Jan. 24, 2013 /PRNewswire/ -- Novus Biologicals LLC, a
leading provider of antibodies and reagents to the life science research
community, has hired David Eansor to lead a new corporate-development effort.

Eansor, a 13-year veteran in the life science market who was most recently the
president of Thermo Fisher Scientific's bioscience division, joined Novus in
January as senior vice-president of corporate development. In this new role,
Eansor is tasked with accelerating Novus' already impressive growth through a
combination of organic investments, licensing and acquisitions of
complementary products and capabilities.

"I'm thrilled to join Novus, and for the opportunity to create new growth
platforms for this innovative company," Eansor said. "I have watched Novus
grow from a niche player to a leader in its space, and I've always been
impressed with its commitment to scientific research and outstanding customer
service."

"We are so pleased to have an executive of David's caliber join our team, and
look forward to many stellar contributions as he expands this critical
corporate-development function for us," added Karen Padgett, Novus' founder
and chief executive.

Before becoming president of the bioscience division of Thermo Fisher, a
publicly traded company, Eansor served as president of the life science
research division, acquiring three businesses during his tenure.

Prior to that, he was president of Cambrex Bioproducts, another life science
research business focused on cell biology. Eansor also spent 19 years with R.P
Scherer Corp., a contract pharmaceutical drug-delivery manufacturer which was
acquired by Cardinal Health. He holds a degree in chemistry from the
University of Western Ontario as well as a bachelor of commerce and an MBA
from the University of Windsor, also in Ontario, Canada.

About Novus

Novus Biologicals is a leading digital marketing-driven, life science company
that supplies antibodies and reagents to the $6 billion global proteomics
market. Novus is known for its breadth of quality antibodies and reagents
that are well recognized by its global customer base. Based in Littleton, CO,
the company was founded in 1996 to license, produce and market antibodies to
support niche and emerging areas of research. Now Novus is a global
enterprise with a catalog of 180,000 products sold in 60 countries, mainly
through its Web site. Novus is backed by Mainsail Partners, a San Francisco
growth-equity firm, and has additional offices in Ontario, Canada and
Cambridge, UK.

CONTACT

Karen Padgett, President and CEO

Novus Biologicals, LLC

Karen@novusbio.com

303-730-1950

www.novusbio.com

SOURCE Novus Biologicals LLC

Website: http://www.novusbio.com
 
Press spacebar to pause and continue. Press esc to stop.